C4 Therapeutics' CFT1946 Phase 1 Abstract Upgraded to ESMO Proffered Paper

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical firm specializing in targeted protein degradation, announced that their preliminary Phase 1 monotherapy abstract for CFT1946 has been elevated to an oral presentation at the ESMO Congress 2024. The presentation, covering CFT1946, a BiDAC™ degrader targeting mutant BRAF V600 solid tumors, will take place on Friday, September 13, 2024, from 4:00 to 5:30 pm CEST.

C4T will also conduct an investor webcast on the same day to discuss the ongoing Phase 1 trial results. The webcast aims to provide detailed insights into the CFT1946 monotherapy data for analysts and investors. Specific details regarding the webcast's timing and access will be shared closer to the event.

C4 Therapeutics is committed to advancing targeted protein degradation science to develop innovative treatments for patients. The company is utilizing its TORPEDO® platform to design and optimize small-molecule medicines aimed at treating challenging diseases. This approach leverages the body's natural protein recycling system to rapidly degrade disease-causing proteins, potentially overcoming drug resistance and improving patient outcomes.

CFT1946, an orally bioavailable BiDAC™ degrader, is specifically designed to target BRAF V600X mutant proteins. Preclinical studies have shown that CFT1946 is effective in vivo and in vitro in models with BRAF V600E-driven diseases, including those resistant to BRAF inhibitors. Currently, CFT1946 is in a Phase 1 dose escalation study targeting various BRAF V600X mutant solid tumors, such as colorectal cancer, melanoma, and non-small cell lung cancer. Further details about this clinical trial can be found on clinicaltrials.gov under the identifier NCT05668585.

C4 Therapeutics is dedicated to transforming patient care by developing next-generation medicines through its pioneering work in targeted protein degradation.